Endometrial Cancer Clinical Trial
— TEACUPOfficial title:
Telephone Follow-up After Treatment for Endometrial Cancer.
NCT number | NCT01610375 |
Other study ID # | TEACUP |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2012 |
Est. completion date | December 2018 |
Verified date | August 2019 |
Source | Queensland Centre for Gynaecological Cancer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to investigate the feasibility, safety and accuracy of a telephone
follow-up for women previously treatment for endometrial cancer.
To achieve this aim, potentially eligible women attending the Queensland Centre for
Gynaecological Cancer (QCGC) outpatient clinic for review following previous treatment for
endometrial cancer will be recruited by this study. The study aims to recruit all new
patients as well as all patients who return to QCGC for their follow-up and who had treatment
within the previous 2 years.
The proposed project will involve generation of an evidence-based checklist of signs and
symptoms of disease recurrence from a thorough literature review. The generated symptom
checklist will be pilot tested and the refined symptom checklist will be used to follow study
participants over a period of 12 months.
During the follow-up period, the basic standard of follow-up after primary treatment for
endometrial cancer at the QCGC, Royal Brisbane and Women's Hospital (RBWH)will not be
altered; however, the study participants will be interview via telephone 2 to 5 days prior to
their scheduled review dates.
The main outcome measure will be the estimated recurrence rate as derived from the telephone
assessment and this will be compared to the clinically detected recurrences as recorded in
patients' medical files.
It is hypothesized, that the telephone follow-up will identify 90% of all recurrences
correctly that are later confirmed during the clinical follow-up.
In addition to the main outcome, we will also assess patients' satisfaction with each of the
follow-up programs, whether or not lifestyle behaviours were queried and support offered to
improve wellbeing.
Status | Completed |
Enrollment | 149 |
Est. completion date | December 2018 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: To be eligible for this pilot study, the patient must; - Have completed primary treatment for endometrial cancer - Be recurrence-free - In the first to third year after treatment - Be able to read and understand English - Must have access to a telephone and adequate hearing - Participants must be willing to complete questionnaire on satisfaction with nurse and clinic follow-up Exclusion Criteria: - Patients with disease recurrent or relapse - Patients with metastatic disease presentation |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Brisbane and Women's Hospital | Herston | Queensland |
Lead Sponsor | Collaborator |
---|---|
Queensland Centre for Gynaecological Cancer |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity, specificity and overall accuracy of the telephone follow-up compared to clinic-based follow-up and patients' satisfaction. | The proposed project will involve generation of an evidence-based checklist of signs and symptoms of recurrence from a thorough literature review. The generated symptom checklist will be pilot tested and used in a one year prospective cohort study. | 12 months | |
Secondary | Changes in lifestyle behaviours and quality of life overtime. | The researcher will conduct a telephone interview and will enquire about the participant's wellbeing and provide resources on physical activity, quality of life, diet, anxiety and depression and supportive care when needed prior to each clinic visit. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02413606 -
ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?
|
N/A |